Jordan Bertrand
UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hôpital d'adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France ; CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.
Med Sci (Paris). 2017 Apr;33(4):441-444. doi: 10.1051/medsci/20173304015. Epub 2017 May 12.
The use of circulating tumour DNA to screen for cancer in asymptomatic individuals is the goal of Grail, initially set up by Illumina. This company is now raising a large amount of capital to develop this project on a much longer time scale than initially announced. Although it has access to cutting edge technology and is led by excellent scientists, the prospect for success in this application is rather bleak, mainly because of the extreme requirements for specificity in order to avoid overdiagnosis.
利用循环肿瘤DNA在无症状个体中筛查癌症是Grail公司的目标，该公司最初由Illumina创立。目前，这家公司正在筹集大量资金，以在比最初宣布的时间长得多的时间范围内开发这个项目。尽管它拥有前沿技术且由优秀科学家领衔，但这一应用的成功前景相当黯淡，主要是因为为避免过度诊断对特异性有极高要求。
